Skip to main content
Skip to main content
CAH logo

Cardinal Health, Inc. (CAH) Stock Analysis

$233.81 -$1.17 (-0.50%) |Exceptional · 90
Cardinal Health, Inc. (CAH) bottom line: signals are mixed — the Council read leans Bullish Lean (70/100) while the AI fundamental score is 90/100 (grade A+); the two lenses disagree, so weigh the breakdown below. Strongest single signal: Seth Klarman bullish.
MCap: $54.8B| P/E Ratio: 32.6| Vol: 398.0K| Target: $248.80 (+6.4%)| 52-wk range: $137.75 – $243.21
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cardinal Health, Inc. (CAH) trades at $233.81 with AI Score 90/100 (Grade A+). Cardinal Health, Inc. is a global healthcare services and products company providing customized solutions to various healthcare providers and patients. Market cap: $54.8B, Sector: Healthcare.

Price as of Aug 19, 2026 · Last analyzed: May 9, 2026
Cardinal Health, Inc. is a global healthcare services and products company providing customized solutions to various healthcare providers and patients. The company operates through its Pharmaceutical and Medical segments, distributing pharmaceuticals and manufacturing medical products.

CAH stock analysis for 2026: Analysts have set a consensus price target of $248.80 for Cardinal Health, Inc., suggesting 6.4% upside from the current price of $233.81. The AI MoonshotScore is 90/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Watch the CAH film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Bullish Lean 70/100 · A

CAH: 2/3 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.

How is this calculated? →
MoonshotScore · Growth Potential · 90/100
Business Quality
Neutral Is this a genuinely good business?
Financial Safety
Strong Could this blow up on me?
Valuation
Strong Am I paying a fair price?
Growth Durability
Strong Is the growth real and likely to last?
Momentum
Moderate Is the market already moving on this?
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Neutral
Izzy Englander
Bullish
Seth Klarman
Bullish
Moon AI
Bullish
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cardinal Health, Inc. (CAH) Healthcare & Pipeline Overview

CEOJason Hollar
Employees47,922
HeadquartersDublin, OH, US
IPO Year1983

Cardinal Health, Inc. (CAH) is a leading integrated healthcare services and products company, providing customized solutions across the pharmaceutical and medical sectors. With a global presence and a focus on distribution and manufacturing, Cardinal Health supports hospitals, pharmacies, and patients, navigating a competitive healthcare landscape.

Data Provenance | Financial Data Quantitative Analysis NYSE Analysis: May 9, 2026

What Is the Investment Thesis for CAH?

As of May 9, 2026 — figures reflect the data available on that date.

Cardinal Health presents a mixed investment thesis. With a market capitalization of $54.8B and a P/E ratio of 32.6, the company's valuation reflects its established position in the healthcare distribution and manufacturing market. A key value driver is the company's diversified revenue streams from both its Pharmaceutical and Medical segments. Growth catalysts include expanding its specialty pharmaceutical services and increasing demand for its branded medical products. However, a low profit margin of 0.6% and gross margin of 3.7% indicate potential challenges in profitability. The dividend yield of 1.11% offers a modest return to investors. Monitoring the company's ability to improve margins and capitalize on growth opportunities in the healthcare sector is crucial. The beta of 0.65 suggests lower volatility compared to the market.

Based on FMP financials and quantitative analysis

CAH Key Highlights

Market Cap of $54.8B reflects its significant presence in the healthcare distribution and manufacturing sector.

  • P/E Ratio of 32.6 indicates investor expectations for future earnings growth.
  • Gross Margin of 3.7% highlights potential areas for improvement in operational efficiency.
  • Dividend Yield of 1.11% provides a modest income stream for investors.
  • Beta of 0.65 suggests lower volatility compared to the broader market, making it a potentially stable investment.

Who Are CAH's Competitors?

CAH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
COR Cencora, Inc. $321.63 +1.74% $62.6B 80
BDX Becton, Dickinson and Company $187.60 +3.78% $51.7B 72
ARGX argenx SE $1032.86 +4.02% $64.2B 49
EW Edwards Lifesciences Corporation $92.28 +1.43% $53.1B 93
HLN Haleon plc $9.85 +1.34% $43.4B 49
ABC AmerisourceBergen Corporation $179.98 -0.23% $36.2B 45
MCK McKesson Corporation $853.71 -1.79% $100.0B 90
HSIC Henry Schein, Inc. $89.29 +0.07% $10.2B 73

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CAH's Key Strengths?

Diversified revenue streams across pharmaceutical and medical segments.

  • Extensive distribution network and supply chain infrastructure.
  • Strong relationships with pharmaceutical manufacturers and healthcare providers.
  • Established brand reputation in the healthcare industry.

What Are CAH's Weaknesses?

Low profit margin compared to industry peers.

  • Exposure to generic pharmaceutical pricing pressures.
  • Dependence on key suppliers and manufacturers.
  • Potential for supply chain disruptions.

What Could Drive CAH Stock Higher?

Expansion of specialty pharmaceutical services, driving revenue growth in a high-margin segment.

  • Increased demand for Cardinal Health branded medical products, enhancing the company's market share.
  • Strategic partnerships and acquisitions, expanding the company's capabilities and geographic reach.
  • Enhancement of supply chain solutions, improving efficiency and customer satisfaction.

What Are the Key Risks for CAH?

Negative return on equity (-55.7%) — the business is not currently generating profit on shareholder capital.

  • Rich valuation — a P/E of 32.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
  • Increased competition from other distributors and manufacturers, potentially impacting market share.
  • Regulatory changes and healthcare reform, creating uncertainty and potential cost pressures.
  • Economic downturns and reduced healthcare spending, affecting revenue and profitability.
  • Product liability claims and recalls, leading to financial losses and reputational damage.
  • Generic pharmaceutical pricing pressures, impacting the profitability of the Pharmaceutical segment.

What Are the Growth Opportunities for CAH?

  • Expansion of Specialty Pharmaceutical Services: Cardinal Health can capitalize on the growing demand for specialty pharmaceutical products and services. By expanding its offerings in this area, including distribution, patient support, and pharmacy management, the company can increase its revenue and market share. The specialty pharmaceutical market is projected to reach $500 billion by 2028, presenting a significant growth opportunity for Cardinal Health. Timeline: Ongoing.
  • Increased Demand for Branded Medical Products: The company's Medical segment can benefit from the increasing demand for Cardinal Health branded medical, surgical, and laboratory products. By focusing on innovation and quality, Cardinal Health can strengthen its brand and expand its customer base. The global medical device market is expected to reach $600 billion by 2027, offering substantial growth potential. Timeline: Ongoing.
  • Strategic Partnerships and Acquisitions: Cardinal Health can pursue strategic partnerships and acquisitions to expand its capabilities and geographic reach. By partnering with or acquiring companies that offer complementary products or services, Cardinal Health can enhance its value proposition and strengthen its competitive position. This includes potential acquisitions in the supply chain management and healthcare technology sectors. Timeline: Ongoing.
  • Enhancement of Supply Chain Solutions: Cardinal Health can further develop its supply chain services and solutions to meet the evolving needs of hospitals, ambulatory surgery centers, and other healthcare providers. By leveraging technology and data analytics, Cardinal Health can improve efficiency, reduce costs, and enhance customer satisfaction. Timeline: Ongoing.
  • Geographic Expansion: Cardinal Health has opportunities to expand its presence in international markets, particularly in Asia and Europe. By entering new markets or expanding its existing operations, Cardinal Health can diversify its revenue streams and reduce its reliance on the U.S. market. The global healthcare market is experiencing rapid growth in emerging economies, presenting significant opportunities for Cardinal Health. Timeline: Ongoing.

What Are CAH's Competitive Advantages?

  • Scale: Cardinal Health's large scale provides it with significant purchasing power and distribution efficiencies.
  • Established Relationships: Long-standing relationships with pharmaceutical manufacturers and healthcare providers create a strong competitive advantage.
  • Integrated Services: The company's integrated services, including pharmaceutical distribution, medical product manufacturing, and supply chain solutions, offer a comprehensive value proposition.
  • Brand Recognition: The Cardinal Health brand is well-recognized and respected in the healthcare industry.

What Does CAH Do?

Cardinal Health, Inc., incorporated in 1979 and headquartered in Dublin, Ohio, operates as an integrated healthcare services and products company across the United States, Canada, Europe, Asia, and internationally. The company provides customized solutions to a diverse range of healthcare providers, including hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. Cardinal Health operates through two primary segments: Pharmaceutical and Medical. The Pharmaceutical segment focuses on the distribution of branded and generic pharmaceuticals, specialty pharmaceutical products, and over-the-counter healthcare and consumer products. This segment also offers services to pharmaceutical manufacturers and healthcare providers, including the operation of nuclear pharmacies and radiopharmaceutical manufacturing facilities. Additionally, it repackages generic pharmaceuticals and over-the-counter products and provides medication therapy management and pharmacy management services. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices. These products include exam and surgical gloves, needles, syringes, sharps disposals, compressions, incontinence products, nutritional delivery products, wound care products, surgical drapes, gowns, fluid suction systems, urology products, operating room supplies, and electrode product lines. The segment also distributes national brand products and provides supply chain services to healthcare providers. Cardinal Health plays a crucial role in the healthcare supply chain, ensuring the efficient delivery of essential products and services.

What Products and Services Does CAH Offer?

  • Distributes branded and generic pharmaceutical products.
  • Provides services to pharmaceutical manufacturers and healthcare providers.
  • Operates nuclear pharmacies and radiopharmaceutical manufacturing facilities.
  • Repackages generic pharmaceuticals and over-the-counter healthcare products.
  • Manufactures and distributes Cardinal Health branded medical, surgical, and laboratory products.
  • Provides supply chain services and solutions to hospitals and other healthcare providers.
  • Assembles and sells sterile and non-sterile procedure kits.

How Does CAH Make Money?

  • Generates revenue through the distribution of pharmaceutical products to pharmacies, hospitals, and other healthcare providers.
  • Earns revenue from the sale of Cardinal Health branded medical products and devices.
  • Provides supply chain and logistics services to healthcare organizations.
  • Offers specialized services such as nuclear pharmacy operations and medication therapy management.

What Industry Does CAH Operate In?

Cardinal Health operates within the medical distribution industry, which is characterized by increasing demand for efficient supply chain solutions and a growing need for pharmaceutical and medical products. The industry is influenced by factors such as aging populations, advancements in medical technology, and regulatory changes. Cardinal Health competes with companies like Cencora, Inc. and Becton, Dickinson and Company, focusing on providing comprehensive healthcare solutions to hospitals, pharmacies, and other healthcare providers. The global healthcare market is expected to continue growing, driven by increased healthcare spending and the rising prevalence of chronic diseases.

Who Are CAH's Key Customers?

  • Hospitals and healthcare systems.
  • Pharmacies (retail and institutional).
  • Ambulatory surgery centers.
  • Clinical laboratories.
  • Physician offices.
AI Confidence: 73% Updated: May 9, 2026

Company Profile

Cardinal Health, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Dublin, US. The company is led by CEO Jason Hollar. CAH has traded publicly since 1983.

Cardinal Health, Inc. Financial Trajectory

Cardinal Health, Inc. (CAH) reported $63.86B in revenue for Q2 2026, reflecting 4.8% growth compared to the prior quarter. The company recorded net income of $394.0M, with diluted EPS of $1.69. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, CAH averaged $1.81 in diluted EPS.

How Cardinal Health, Inc. Is Valued

Cardinal Health, Inc. carries a market capitalization of $54.8B, placing it in the large-cap category. Relative to its peer group, CAH's quantitative score of 90/100 is above the peer average of 69/100.

ROE -56%

Key Financial Metrics

Return on equity for Cardinal Health, Inc. stands at -55.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.8%, showing how much profit it generates from its asset base. CAH trades at a trailing price-to-earnings ratio of 32.60, above the Healthcare sector average of ~23x. Its free cash flow yield is 8.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.91 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 3.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 7/9

Financial Health

Cardinal Health, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.07 places it in the safe zone, indicating low near-term bankruptcy risk.

8/8 beats

Earnings Track Record

Cardinal Health, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 12.6% above estimates on average.

FY2026 est

Forward Outlook

Wall Street analysts project Cardinal Health, Inc. revenue of about $255.87B for fiscal 2026, with EPS near $10.78. The estimate reflects 12 contributing analysts.

Net buying

Insider Activity

Over the past six months, Cardinal Health, Inc. insiders filed 11 SEC Form 4 transactions — 2 sales and 9 purchases. On net that is roughly 416K shares acquired (about $548K) — insiders putting money in tends to read as conviction.

CAH Financials

Fundamental Snapshot

Revenue Growth (FY)
+14.2%
Net Income Growth (FY)
+9.8%
EPS Growth (FY)
+12.2%
Free Cash Flow Growth (FY)
+144.6%
P/E (TTM)
32.6
Return on Equity (TTM)
-55.7%
Current Ratio
0.9
EV/EBITDA (TTM)
18.3

Based on FMP financials and quantitative analysis · FY 2026

Bull Case vs Bear Case

Bull Case

  • Cardinal Health seems to be quietly gaining traction in the healthcare supply chain, with whispers of operational efficiencies improving.
  • Recent insider buying activity suggests that those closest to the company see long-term value.
  • The community seems to be acknowledging Cardinal Health's stability in a volatile market, viewing it as a safe haven.
  • There's a growing perception that Cardinal Health is undervalued compared to its peers, sparking interest among value investors.

Bear Case

  • The overall healthcare sector faces regulatory headwinds, and Cardinal Health isn't immune to these pressures.
  • Community discussions reveal concerns about potential legal liabilities related to opioid distribution.
  • Market perception suggests that Cardinal Health might be slow to adapt to emerging trends in healthcare technology.
  • Some investors worry that Cardinal Health's growth prospects are limited compared to more innovative healthcare companies.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026

From the Earnings Call

“Segment revenue grew 11% to $56.1 billion. This was primarily driven by existing customer growth across the portfolio... Of note, during Q3, GLP-1s added 6 percentage points to our revenue growth... The growth from GLP-1s was generally offset in the quarter by a 6 percentage point impact to revenue from inflation reduction at WAC pricing adjustments.”

— Aaron Alt

“Segment revenue grew 31% to $1.7 billion and segment profit grew 34% to $179 million... However, we are increasing our profit growth guidance to a range of 36% to 38%, up from 33% to 35%.”

— Aaron Alt

CAH Q3 FY2026 earnings call transcript · 2026-04-30

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q2 2026 $63.86B $394M $1.69
Q1 2026 $60.94B $399M $1.69
Q4 2025 $65.44B $471M $1.97
Q3 2025 $64.01B $450M $1.88

Based on FMP financials and quantitative analysis

CAH Latest News

CAH Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CAH.

Price Targets

Consensus target: $248.80

CAH MoonshotScore

90/100

What does this score mean?

The MoonshotScore rates CAH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Latest Cardinal Health, Inc. Analysis

Leadership: Jason Hollar

CEO

Jason Hollar serves as the Chief Executive Officer of Cardinal Health, bringing extensive experience in finance and operations. Prior to his appointment as CEO, Hollar served as the Chief Financial Officer of Cardinal Health, where he was responsible for overseeing the company's financial strategy and performance. His background includes leadership roles at various companies, providing him with a broad understanding of the healthcare industry and financial management. Hollar's expertise encompasses strategic planning, financial analysis, and operational excellence.

Track Record: Since becoming CEO, Jason Hollar has focused on driving operational efficiencies and expanding Cardinal Health's presence in key markets. He has emphasized innovation and customer-centric solutions to enhance the company's competitive position. Under his leadership, Cardinal Health has continued to navigate the evolving healthcare landscape and deliver value to its stakeholders.

Common Questions About CAH (Healthcare)

What does the AI Score mean for CAH?

CAH holds an AI Score of 90/100 (Grade: A+). This is an educational research signal, not a buy or sell recommendation. Cardinal Health, Inc. is a global healthcare services and products company providing customized solutions to various healthcare providers and patients. The company operates through its …

What does Cardinal Health, Inc. do?

Cardinal Health, Inc. operates as an integrated healthcare services and products company, providing customized solutions to hospitals, pharmacies, and other healthcare providers. The company distributes branded and generic pharmaceuticals, manufactures medical products, and offers supply chain services. Cardinal Health's business model focuses on providing comprehensive solutions to its customers, ensuring the efficient delivery of essential products and services.

What do analysts say about CAH stock?

Analyst consensus on Cardinal Health stock reflects a cautiously optimistic outlook, recognizing the company's established position in the healthcare distribution and manufacturing market. Key valuation metrics, such as the P/E ratio and dividend yield, are closely monitored. Growth considerations include the company's ability to expand its specialty pharmaceutical services and manage pricing pressures in the generic pharmaceutical market.

What are the main risks for CAH?

Cardinal Health faces several key risks, including increased competition from other distributors and manufacturers, regulatory changes and healthcare reform, economic downturns and reduced healthcare spending, and product liability claims and recalls. The company is also exposed to generic pharmaceutical pricing pressures, which can impact the profitability of its Pharmaceutical segment.

What are the key factors to evaluate for CAH?

Cardinal Health, Inc. (CAH) holds an AI score of 90/100 (high). P/E: 32.6x vs the S&P 500's ~20-25x. Analysts target $248.80 (+6%). Not financial advice.

How frequently does CAH data refresh on this page?

CAH's price was last updated on Aug 19, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven CAH's recent stock price performance?

Cardinal Health, Inc. (CAH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified revenue streams across pharmaceutical and medical segments. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CAH overvalued or undervalued right now?

Cardinal Health, Inc. (CAH) trades at 32.6x earnings. Analysts target $248.80 (+6%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CAH before investing?

Before investing in Cardinal Health, Inc. (CAH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available reporting period.
Data Sources

Popular Stocks

More Stocks We Cover